Royalty Pharma

Transforming the Funding of Life Sciences Through Collaborative Capital

We work directly with innovators across the life sciences, including research institutions, inventors, and biopharma companies

APPROVED PRODUCT ROYALTY MONETIZATION

The biopharmaceutical industry is undergoing a period of strong growth and unprecedented innovation We intend to further this innovation by acquiring royalties on leading biopharmaceutical products

We seek to acquire royalties on innovative product candidates in the late-stages of clinical development We collaborate directly with innovators to acquire a new synthetic royalty, monetize an existing royalty or provide capital to an innovator to co-fund clinical development of a product candidate in exchange for a royalty

We take a flexible approach to acquisitions In biopharmaceutical acquisitions, the focus of an acquirer is typically on strategic assets over which the target has operational control, rather than on passive financial assets such as royalties We can partner with strategic acquirers which buy companies that own both strategic assets and passive royalties